Last reviewed · How we verify
IM-01
At a glance
| Generic name | IM-01 |
|---|---|
| Also known as | Chicken egg-derived anti-C.difficile polyclonal antibodies |
| Sponsor | ImmuniMed Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Mild-moderate Clostridium Difficile Infection (CDI) (PHASE2)
- A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM-01 CI brief — competitive landscape report
- IM-01 updates RSS · CI watch RSS
- ImmuniMed Inc. portfolio CI